This week, we talk about the continuing hurdles preventing a vaccine from reaching Brazilians. And the question marks around the upcoming election in Congress.
Brazil’s vaccines hit regulatory hurdles
On Friday, federal health regulatory agency Anvisa received requests for the emergency approval of two coronavirus vaccines: one developed by AstraZeneca (the federal government’s main bet) and the Chinese-made CoronaVac. Over the weekend, the agency said AstraZeneca had filed all necessary documents, while demanding more information from the São Paulo-based Butantan Biological Institute, responsible for CoronaVac trials in Brazil.
- The move once again sparked concerns that Anvisa could be suffering...